Introduction
Chronic liver injury results in liver fibrosis, which may progress to cirrhosis (31, 42, 45) , increasing the risk of developing hepatocellular carcinoma (HCC) (52) . Liver fibrosis, a maladaptive form of wound healing, results from the interplay of various intra-and extra-hepatic cells activated by a wide variety of cytokine and growth factor mediators (15, 23) . Hepatic stellate cells (HSCs) and portal fibroblasts are recognized as the primary cellular mediators of fibrosis as they produce collagen (15, 29, 42, 57) . Understanding the molecular pathways involved in coordinated activation and inactivation of HCSs and/or myofibroblasts in fibrogenesis is critical to the development of anti-fibrotic therapies.
A plethora of cytokines, chemokines, growth factors and extracellular factors are involved in HSC activation, proliferation and migration (22, 46, 59) . Two families of growth factors appear to be critical regulators of HSCs; transforming growth factor beta (TGFβ) ligands, and platelet derived growth factor (PDGF) ligands (46) . The PDGF ligand family, PDGF-A, B, C, and D, transmit their extracellular signals via tyrosine kinase receptors, PDGF receptor α (PDGFRα) and β (PDGFRβ) (1, 5) . Stimulation of PDGF receptors induces HSCs proliferation in vitro (44, 60) , and overexpression of PDGF-A, -B, or -C in the liver(7, 9, 53) results in fibrosis.
Hepatic overexpression of PDGF-C results in progressive liver disease, development of tumors, and decreased life span(7), phenotypes not seen when PDGF-A or -B are overexpressed in the liver(9, 53). It is not yet known how the overexpression of these different PDGF ligands results in different liver pathology. Thieringer and Czochra have suggested that the different outcomes may reside with differences in PDGF ligands to stimulate transforming growth factor beta (TGFβ) ligands(7, 9, 53).
TGFβ is a multifunctional cytokine that regulates cell survival, differentiation, migration and synthesis of extracellular matrix (ECM) components (12, 25, 58) . Elevated levels of TGFβ are seen in organ fibrosis and, Tgfβ overexpression results in liver fibrosis (50) (27) . TGFβ stimulates type I collagen production, the hallmark of liver fibrosis, as well as regulating fibrinolysis factors, such as matrix metalloproteinases (MMPs) and their inhibitors (12, 25, 58) .
TGFβ binds to cell surface receptors to initiate a number of intracellular signal transduction pathways, including activation of Smad proteins, which are transcription factors(12, 25, 58).
TGFβ ligand binding stimulates receptor phosphorylation of Smad2 and 3, allowing binding with Smad4 forming complexes that translocate to the nucleus to activate gene expression. Among the genes induced by Smad2/Smad3:Smad4 complexes is the inhibitory Smad, Smad7. Smad7 is regulated by Smad2/3 transcriptional activity and disrupts receptor activation of Smad2/3, which inhibits TGFβ signaling in a negative feedback loop (34, 38, 39) .
We have previously reported that hepatic overexpression of PDGF-C results in progressive liver fibrosis, which increases in severity as the mice age, and eventually the development of HCCs(7). Shortly after birth, extensive HSC activation and proliferation is apparent, accompanied by elevated hepatic Tgfβ1 (7, 8) . Correlation between collagen deposition, HSC activation and elevated levels of Tgfβ1 suggests that TGFβ may be critical regulator in this mouse model of fibrosis. In other hepatic transgenic PDGF mouse strains, increased expression of TGFβ was reported for PDGF-A(53), but not PDGF-B(9). Thus, it is plausible that differences in the amount of TGFβ produced in each of these models (7, 9, 53) may account for the observed differences in the severity of chronic liver disease in these models.
In this study we sought to investigate whether TGFβ regulates PDGF-C-induced liver fibrogenesis by interfering with TGFβ signaling pathways, by deleting the Smad3 allele. To test this hypothesis, we generated PDGF-C Tg mice that also lacked Smad3 and found that PDGF-C;Smad3 KO mice had less fibrosis compared to PDGF-C Tg mice. Gene expression studies revealed that collagen gene expression was Smad3-dependent, while genes associated with HSCs activation were not significantly decreased in PDGF-C;Smad3 KO mice. Isolated Smad3 null HSCs grew more slowly than wild type HSCs. In vitro, PDGF ligands stimulated TGFβ protein production and release. In summary, these data indicate that Smad3 is an important mediator of PDGF-C-induced fibrosis, and delineated the contributions of TGFβ/Smad3 pathways in this model. PDGF-C regulates both Smad3-dependent and independent signaling pathways. Thus, combination therapy that targets both TGFβ-and PDGF signaling pathways may provide the most effective long-term therapy for chronic liver disease and prevention of HCC.
Materials and Methods
Generation of PDGF-C Tg;Smad3-deficient mice PDGF-C transgenic (PTg) mice(7) and Smad3 deleted mice with targeted disruption of exon 8 in the Smad3 gene (Smad3KO ex8/ex8 ) have been previously described (62 
RNA isolation and real-time RT-PCR analysis
RNA was isolated from whole liver snap frozen at the time of necropsy using TRIzol (Invitrogen, now Life Technologies, Carlsbad, CA) according to the manufacturer's recommendation. For cDNA synthesis, 2 µg RNA was reverse transcribed using the Retroscript kit (Life Technologies, Carlsbad, CA), and real-time RT-PCR (qPCR) was performed using FAM-labeled primers (Applied Biosystem, Forster City, CA) as described or primers used with Sybr Green (primer sequences are available on request). Gene expression data are normalization to Gapdh mRNA or 18S rRNA levels using the ∆∆Ct method as previously described(61).
Protein extraction and immunoblotting
Whole liver lysates were prepared using a Triton-X 100 lysis buffer with protease inhibitors and quantified using the Bradford method with BSA(8). SDS-PAGE analysis of proteins levels were determined using immunoblotting and the following antibodies: rabbit anti-Smad3 (Zymed, Carlsbad, CA), rabbit anti-Smad2 (Zymed, South San Francisco, CA), mouse anti-Smad4
(Santa Cruz, Santa Cruz, CA), mouse anti-human αSMA (DAKO, Carpinteria, CA), and rabbit anti-GAPDH conjugated to HRP (GeneScript, Piscataway, NJ). Epitope-primary antibody complexes were detected with species-specific secondary antibodies conjugated to HRP followed by ECL (Thermo Fisher Scientific Pierce, Illinois).
Primary HSC isolation and culture conditions
HSCs were isolated from WT and KO mice (i.e. Smad3 ex8/ex8 ), using pronase/collagenase(36, 56) perfusion and density centrifugation methods using Nycodez. Isolated HSCs were cultured on uncoated tissue culture dishes (1-4 x 10 4 cells/cm 2 ) in DMEM supplemented with 10% FBS and penicillin in 95% air 5% CO 2 humidified atmosphere at 37°C. After seven days, cultures were placed in serum-free media and incubated with serum-free media or with PDGF-CC in serum-free media for 24 hrs. Typically isolated HSCs were combined from two to three mice.
Stocks solutions of TGFβ (R&D Systems) were prepared according to the manufacturer's directions.
Cell proliferation in primary HSCs cells.
[ 3 H]Thymidine incorporation or cell counting were used to measure cell proliferation as previously described(3, 7). Primary HSCs were isolated from 6 to 7 week old WT mice or
Smad3 KO mice and maintained as described in the previous section. In some experiments HSC cultures were serum starved overnight prior to ligand treatment and subsequent addition
Detection of TGFβ1 in HSC media.
Rat CFSC-2G stellate cell cultures were maintained as described by Greenwel and coworkers (18) . CFSC-2G cells were serum-starved overnight with BSA, treated with the indicated doses of PDGF-CC and -DD (a gift from ZymoGenetics(17)) -AA, -AB or -BB (R&D Systems), and cell culture media was collected 24 to 72 h later. TGFβ protein levels were determined by ELISA (R&D Systems Quantikine Human Immunoassay cat# DB100B) after media was treated with HCl to convert latent TGFβ to the active form. This assay recognizes human porcine, mouse, rat and canine TGFβ1, but not other TGFβ isoforms.
Statistical analysis
All results are shown as mean ± standard error of the mean (SE). Data were analyzed using non-parametric analyses, including Mann-Whitney test, or Kruskal-Wallis with multiple comparisons with Dunn's posttest. P<0.05, (*) was considered as statistically significant.
Statistical analyses were performed with SPSS version 12.0 software for Windows (SPSS Inc., Chicago, IL, USA) or Prism (GraphPad Software, CA, USA).
Results
Elevated TGFβ/Smad signaling in fibrotic liver tissue from PDGF-C Tg mice. PTg mice develop pericellular and perivenular hepatic fibrosis that progresses to bridging fibrosis as the mice age(7, 8). As TGFβ is a potent pro-fibrotic molecule in many different tissues(13, 16), we hypothesized that TGFβ signaling pathways contributed to the development and progression of fibrosis observed in this model. Previously, we observed that Tgfβ1 mRNA was elevated in PDGF-C PTg mice compared to WT littermates(7). Additionally, cDNA microarray analysis revealed that genes in the TGFβ signaling pathway, including several Smads, were significantly up-regulated in liver tissue from PDGF-C PTg relative to WT mice(61) (GEO number GSE38199). To provide further evidence of TGFβ signaling, we performed real-time PCR, immunoblot and immunohistochemical analyses on liver tissue from eight to nine week old WT and PTg mice ( Fig.1) . We observed elevated levels of TGFβ1 receptor 1 (TgfβrI) mRNA ( Fig.1,A1 ), Smad3 (Fig. 1A. 2), but not Smad2 (Fig. 1, A. 3) in PDGF-C PTg compared to
WTmice. In addition, expression of Smad7, a transcriptional target of Smad2/3, was also induced ( 
Deletion of Smad3 in PDGF-C Tg mice reverses phenotypic changes induced by PDGF-C.
If PDGF-C-induced liver fibrosis is dependent on TGFβ production and TGFβ regulates collagen production, then disruption of TGFβ signaling pathways should attenuate fibrosis in PTg mice had circulating levels of active ligand, and no significant differences were seen between PTg and PTg/KO mice (Fig. 2B) . Thus, changes in transgene expression do not appear to account for differences in observed liver phenotypes.
PTg mice have greater liver weight to body weight ratios than WT littermates (17) , and systemic Smad3 deletion resulted in a statistically significant decrease in liver weight/body weight in PTg mice (Fig. 2C) . PDGF-C overexpression also increases the spleen weight relative to body weight, a phenotype that was also partially reversed by deletion of Smad3 (Fig. 2D ).
Liver cell proliferation is enhanced in PTg mice(7, 8); deletion of Smad3 decreased both hepatocyte ( Fig. 2E ) and NPC proliferation ( 
Smad3 null HSCs proliferate slowly.
In this study we have shown that NPC proliferation in vivo was significantly decreased in PTg/KO mice compared with PTg mice (Fig. 2F) . We thus wondered whether TGFβ effects could be observed in isolated primary HSCs from KO mice would be differentially affected by TGFβ (Fig. 3) . In vitro, TGFβ has different effects on cell growth depending on a variety of factors, including the embryologic origin of the cell and its degree of activation or transformation.
Mesenchymal cells such as myofibroblasts proliferate or trans-differentiate in response to TGFβ(5, 46, 58) . To evaluate the effect of Smad3 gene deletion on HSC proliferation, HSCs were isolated from both WT and KO mice, and cell proliferation was assessed. Primary HSCs isolated from KO mice grew more slowly on plastic dishes than WT HSCs (Fig. 3A) . WT cells doubled in approximately two days, while Smad3 KO HSCs took four days nearly twice as long to double in number. Nonetheless Smad3 null HSCs were able to proliferate, albeit slowly. To evaluate the effect of Smad3 gene deletion on PDGF-CC-stimulated HSC proliferation, we next plated cultured primary HSCs from WT and Smad3 KO mice on plastic for seven days, which allowed them to become activated and myofibroblast-like. After removing the serum, the cultures were exposed to PDGF-CC and cell proliferation was measured. PDGF-CC-induced HSC proliferation was significantly attenuated in Smad3 null HSCs (Fig.3B ). Thus Smad3 null
HSCs grow more slowly than WT HSCs in the presence of either serum or PDGF-CC in culture.
These in vitro results mirror the decreased NPC proliferation observed in vivo in livers of
PTg/KO mice (Fig. 2F) .
Deletion of Smad3 ameliorates PDGF-C induced liver fibrosis.
To investigate the role of Smad3 on PDGF-C-induced liver fibrosis, collagen deposition was examined in fixed liver tissues using Masson's trichrome and picrosirius red staining (Fig. 4) .
Architectural derangement of liver and deposition of fibrous filaments was apparent in PTg mouse specimens, but was diminished in PTg/KO mice ( Fig. 4C and 4D ). Collagen staining was attenuated in 3-month-old PDGF-C Tg;Smad3 KO mice compared to PDGF-C Tg mice as detected by trichrome ( Fig. 4A and 4C ) or picrosirus red ( Fig. 4B and 4D ) staining. Liver specimens from WT and Smad3 KO mice had little collagen deposition, which was less than that seen in PDGF-C Tg;Smad3 KO mice. Differences in collagen deposition were not apparent between WT and Smad3 KO strains (data not shown).
To quantify the differences in collagen deposition, we performed morphometric analysis on picrosirius red stained liver tissue from WT, KO, PTg and PTg/KO mice (Fig. 5) . Liver fibrosis was significantly decreased in PTg/KO mice compared to PDGF-C PTg mice. Loss of Smad3 in PTg mice did not fully reverse the collagen deposition to the levels seen in uninjured WT and KO mice, however. Together these results indicate that TGFβ/Smad3 signaling pathways partially regulate drive PDGF-C-induced fibrogenesis.
Smad3 regulates hepatic gene expression in PDGF-C Tg mice.
Smad3, a critical component of the canonical TGFβ signaling pathway, transcriptionally regulates expression of genes that contributes to fibrosis. To assess the consequences of Smad3 deletion on PDGF-C-induced changes in gene expression, we performed real-time RT PCR analyses using whole liver RNA from WT, KO, PTg and PTg/KO mice (Fig. 6) . PDGF-C overexpression induces collagen α1(I) (Col1a1), collagen α2(I) (Col2a1), and collagen α1(IV) (Col4a1) expression in the livers of PTg mice, but this induction was blocked in PTg/KO mice (Fig. 6A) . Increased smooth muscle α-actin (αSMA, Acta2) is a hallmark of liver fibrosis and is associated with HSC activation. PTg/KO mice have less Acta2 mRNA than PTg mice.
Connective tissue growth factor (CTGF, Ctgf) is regulated by TGFβ and is implicated in the regulation of a number of collagen genes(40, 47). PDGF-C overexpression up-regulates Ctgf
expression, which is attenuated in PTg/KO mice.
PDGF-C Tg mice induce hepatic genes that are Smad3-independent.
We have previously reported the overexpression of PDGF-C results in the induction of number genes, including Tgfβ1 and the PDGF receptors, Pdgfrα and Pdgfrβ(7, 61). In these experiments, we observed a similar induction of these genes in PTg mice, but their expression was not significantly changed when Smad3 was deleted in PTg/KO mice (Fig. 6B) . These results suggest that Smad3-independent-or additional signaling pathways regulate cellular retinol binding protein 1 (Crbp1), Tgfβ1, Pdgfrα and Pdgfrβ gene expression in the PTg liver.
Since these genes are often associated with HSC activation and/or proliferation (25, 26, 43, 59), our results suggest that HSC activation may be dependent on PDGF-C-mediated pathways to a greater extent than those mediated by Smad3.
Discussion
TGFβ and PDGF signaling pathways are important regulators of liver fibrosis. However, how these signaling pathways collaborate in liver fibrogenesis is not well understood. The major finding of this study is that PDGF-C-induced hepatic fibrosis is dependent on TGFβ signaling that is regulated by Smad3. Overexpression of PDGF-C results in activation of HSCs, and fibrosis, which increases with severity as Tg mice age. As Tgfβ1 levels are elevated in PDGF-C Tg mice compared to WT mice, we suspected that part of the fibrotic potency of PDGF-C was due to activation of TGFβ signaling pathways. Using a genetic approach, we showed that PTg mice that lack Smad3 have decreased liver and spleen mass, and less collagen deposition compared to PTg mice with intact Smad3. Using in vitro approaches we show that PDGF ligands have the capability to stimulate TGFβ production. These data suggest the following sequence of events in PDGF-C-induced fibrosis. PDGF-C induces Tgfβ expression, which drives the expression and deposition of collagen, resulting in fibrosis. In addition to TGFβ's effects on HSCs, PDGF-C also directly stimulates the proliferation and activation of HSCs.
Our findings are consistent with previous studies in liver fibrosis indicating that Smad3 is a key regulator of collagen deposition. Schnabl and co-workers (51) showed that Col1a1 expression was decreased, while αSMA expression was not after acute carbon tetrachloride (CCl 4 ) injury in Smad3KO exon1 mice. In the present study, Smad3 deletion had a more profound effect on collagen deposition than αSMA expression (Fig. 4 and 5) , consistent with reports of less fibrosis in a dimethlynitrosamine model of liver fibrosis using Smad3KO ex8/ex8 mice(30).
Smad3 KO mice have altered mechano-transduction properties due, in part, to changes in ECM production(2), which are supported by in vitro studies demonstrating that Smad3 regulates cytoskeletal organization(55). Not surprisingly, the role of Smad3 in fibrosis or cirrhosis also depends on the type of fibrotic injury (28), and possibly the underlying etiology in human fibrosis.
It is interesting to note that genetic Smad3 deletion altered the expression of Ctgf, but not Tgfβ in PTg livers. In this model it is surprising that Tgfβ expression was not significantly decreased in PTg/KO mice, because this profibrotic molecule is regulated in an autocrine manner (14, 43) , and thus would have been expected to be 'downstream' of Smad3. Our studies
show that collagen levels decreased despite unchanged levels of Tgfβ gene expression. In our studies, decreased Ctgf expression correlated with decreased collagen gene expression and collagen deposition, suggesting that CTGF is a key fibrogenic regulator that is dependent on Smad3. However, recent studies have demonstrated that Ctgf induction is Smad3-independent, a relationship that may depend on the cell type or injury model that is used (19, 20, 33) .
In vivo Smad2 and Smad3 have independent functions as revealed by genetic deletion studies (62) . Deletion of Smad2 is embryonic lethal, while Smad3 deletion is permissive during development, regardless of the targeting construct(10, 62, 65). Similarly, Smad3 has separate, non-overlapping functions from Smad2 in hepatic fibrogenesis and HSC activation. In hepatocytes, Smad2 represses cell growth after injury, while Smad3 blocks apoptosis (26) . In the present studies, we did not find evidence that Smad2 compensated for loss of Smad3. Thus, Smad2 and Smad3 regulate different physiological functions despite being 87% similar in amino acid sequence.
Smad3 deletion did not fully reverse effects of PDGF-C overexpression, however. This result was not unexpected as TGFβ stimulates a number of intracellular signaling pathways that are Smad-independent(11, 34, 38). Smad3-independent pathways that play key regulatory mice crossed with PDGF-C Tg mice (i.e. PTg/KO mice) had similar mortality as mice that only lacked the Smad3 allele. While it appears that the PDGF-C transgene does not appear to modify the effects of the systemic deletion of Smad3, the high mortality of these mice precluded analysis of hepatocellular carcinogenesis, which develops around 6 to 7 months of age. Thus, it remains to be determined whether attenuation of fibrosis by blocking TGFβ signaling via Smad3 would result in decreased incidence or prevalence of HCC in this model.
The present study, along with many other studies, provides strong evidence that targeting TGFβ signaling in chronic liver disease would ameliorate liver fibrosis or cirrhosis if selective therapies could be developed. This anti-fibrotic approach continues to be revised in light of recent studies and previous attempts to block TGFβ signaling in pre-clinical models (49) .
The challenge of blocking TGFβ signaling is that this cytokine has cell-specific roles that continually change depending on disease type and stage, which may lead to unanticipated side effects(4). Moreover, our studies suggest that PDGF-C regulates TGFβ signaling pathways and that block of both these signaling pathways may be required for effective long-term therapy for chronic liver disease and prevention of HCC. 
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